3 Drugs Stocks Moving The Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 79 points (-0.5%) at 16,635 as of Friday, Aug. 15, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,072 issues advancing vs. 1,895 declining with 174 unchanged.

The Drugs industry currently sits down 0.9% versus the S&P 500, which is down 0.3%. Top gainers within the industry include Salix Pharmaceuticals ( SLXP), up 2.8%, and Jazz Pharmaceuticals ( JAZZ), up 2.8%. On the negative front, top decliners within the industry include Teva Pharmaceutical Industries ( TEVA), down 1.1%, Abbott Laboratories ( ABT), down 1.0%, Sanofi ( SNY), down 0.8%, Novartis ( NVS), down 0.8% and GlaxoSmithKline ( GSK), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Allergan ( AGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Allergan is up $2.25 (1.4%) to $157.85 on average volume. Thus far, 1.5 million shares of Allergan exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $156.30-$160.83 after having opened the day at $156.30 as compared to the previous trading day's close of $155.60.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $46.0 billion and is part of the health care sector. Shares are up 39.5% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts who rate Allergan a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Allergan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Actavis ( ACT) is up $3.09 (1.4%) to $215.73 on average volume. Thus far, 1.5 million shares of Actavis exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $213.92-$218.28 after having opened the day at $214.00 as compared to the previous trading day's close of $212.64.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $54.7 billion and is part of the health care sector. Shares are up 23.2% year-to-date as of the close of trading on Thursday. Currently there are 16 analysts who rate Actavis a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $1.54 (1.6%) to $97.90 on heavy volume. Thus far, 11.4 million shares of Gilead exchanged hands as compared to its average daily volume of 11.2 million shares. The stock has ranged in price between $97.02-$99.37 after having opened the day at $98.42 as compared to the previous trading day's close of $96.36.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $142.1 billion and is part of the health care sector. Shares are up 25.1% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts who rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists